After finishing at $3.34 in the prior trading day, Cellectar Biosciences Inc (NASDAQ: CLRB) closed at $3.49, up 4.49%. In other words, the price has increased by $+0.1500 from its previous closing price. On the day, 1168951 shares were traded.
Ratios:
Our goal is to gain a better understanding of CLRB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.22 and its Current Ratio is at 1.22. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLRB now has a Market Capitalization of 41.04M and an Enterprise Value of 24.01M.
Stock Price History:
Over the past 52 weeks, CLRB has reached a high of $4.38, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is 3.2538, while the 200-Day Moving Average is calculated to be 2.3575.
Shares Statistics:
The stock has traded on average 1.49M shares per day over the past 3-months and 806.41k shares per day over the last 10 days, according to various share statistics. A total of 12.29M shares are outstanding, with a floating share count of 11.80M. Insiders hold about 3.94% of the company’s shares, while institutions hold 79.73% stake in the company. Shares short for CLRB as of Jan 31, 2024 were 1.89M with a Short Ratio of 1.26, compared to 541.13k on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 15.34% and a Short% of Float of 15.39%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$1 for the current quarter, with a high estimate of -$0.69 and a low estimate of -$1.43, while EPS last year was -$0.9. The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.7 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.61 and -$4.72 for the fiscal current year, implying an average EPS of -$3.91. EPS for the following year is -$2.83, with 5 analysts recommending between -$1.32 and -$5.15.
